Aclaris Therapeutics, Inc. (ACRS) — Analyst outlook / Analyst consensus target is. Based on 16 analyst ratings, the consensus is bullish — 13 Buy, 3 Hold.
The consensus price target is $10.00, representing an upside of 155.1% from the current price $3.92.
Analysts estimate Earnings Per Share (EPS) of $-0.82 and revenue of $0.01B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1.71 vs est $-0.82 (missed -108.5%). 2025: actual $-0.53 vs est $-0.53 (missed -0.8%). Analyst accuracy: 74%.
ACRS Stock — 12-Month Price Forecast
$10.00
▲ +155.10% Upside
Average Price Target
Based on 16 Wall Street analysts offering 12-month price targets for Aclaris Therapeutics, Inc., the price target is $10.00.
The average price target represents a +155.10% change from the last price of $3.92.
ACRS Analyst Ratings
Buy
Based on 16 analysts giving stock ratings to Aclaris Therapeutics, Inc. in the past 3 months
EPS Estimates — ACRS
74%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024
Actual –$1.71
vs Est –$0.82
▼ 52.0% off
2025
Actual –$0.53
vs Est –$0.53
▼ 0.8% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — ACRS
75%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024
Actual $0.019B
vs Est $0.012B
▲ 38.0% off
2025
Actual $0.008B
vs Est $0.009B
▼ 12.0% off
Revenue Trend
Revenue has declined over the period shown. Analysts forecast significant revenue growth ahead.
